175 related articles for article (PubMed ID: 35070257)
1. Lee Silverman Voice Treatment to Improve Speech in Parkinson's Disease: A Systemic Review and Meta-Analysis.
Pu T; Huang M; Kong X; Wang M; Chen X; Feng X; Wei C; Weng X; Xu F
Parkinsons Dis; 2021; 2021():3366870. PubMed ID: 35070257
[TBL] [Abstract][Full Text] [Related]
2. Lee Silverman Voice Treatment for dysarthria in patients with Parkinson's disease: a systematic review and meta-analysis.
Yuan F; Guo X; Wei X; Xie F; Zheng J; Huang Y; Huang Z; Chang Z; Li H; Guo Y; Chen J; Guo J; Tang B; Deng B; Wang Q
Eur J Neurol; 2020 Oct; 27(10):1957-1970. PubMed ID: 32539227
[TBL] [Abstract][Full Text] [Related]
3. Lee Silverman Voice Treatment (LSVT)-BIG to improve motor function in people with Parkinson's disease: a systematic review and meta-analysis.
McDonnell MN; Rischbieth B; Schammer TT; Seaforth C; Shaw AJ; Phillips AC
Clin Rehabil; 2018 May; 32(5):607-618. PubMed ID: 28980476
[TBL] [Abstract][Full Text] [Related]
4. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
Trials; 2020 May; 21(1):436. PubMed ID: 32460885
[TBL] [Abstract][Full Text] [Related]
5. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
[TBL] [Abstract][Full Text] [Related]
6. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.
Ramig LO; Sapir S; Countryman S; Pawlas AA; O'Brien C; Hoehn M; Thompson LL
J Neurol Neurosurg Psychiatry; 2001 Oct; 71(4):493-8. PubMed ID: 11561033
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
Finnimore A; Theodoros D; Rumbach AF
Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Lee Silverman Voice Treatment® LOUD on Japanese-Speaking Patients with Parkinson's Disease.
Nakayama K; Yamamoto T; Oda C; Sato M; Murakami T; Horiguchi S
Rehabil Res Pract; 2020; 2020():6585264. PubMed ID: 32411475
[No Abstract] [Full Text] [Related]
9. Comparison of speech and language therapy techniques for speech problems in Parkinson's disease.
Herd CP; Tomlinson CL; Deane KH; Brady MC; Smith CH; Sackley CM; Clarke CE
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002814. PubMed ID: 22895931
[TBL] [Abstract][Full Text] [Related]
10. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
[TBL] [Abstract][Full Text] [Related]
11. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
[TBL] [Abstract][Full Text] [Related]
12. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
[TBL] [Abstract][Full Text] [Related]
13. Neurobehavioral Effects of LSVT
Li Y; Tan M; Fan H; Wang EQ; Chen L; Li J; Chen X; Liu H
Front Neurosci; 2021; 15():624801. PubMed ID: 33716652
[TBL] [Abstract][Full Text] [Related]
14. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
Wight S; Miller N
Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
[TBL] [Abstract][Full Text] [Related]
15. Impact of the LSVT on vowel articulation and coarticulation in Parkinson's disease.
Sauvageau VM; Roy JP; Langlois M; Macoir J
Clin Linguist Phon; 2015 Jun; 29(6):424-40. PubMed ID: 25688915
[TBL] [Abstract][Full Text] [Related]
16. PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention.
Finnimore A; Theodoros D; Rumbach AF
Int J Lang Commun Disord; 2022 Jan; 57(1):138-151. PubMed ID: 34767290
[TBL] [Abstract][Full Text] [Related]
17. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
[TBL] [Abstract][Full Text] [Related]
18. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease.
Deane KH; Whurr R; Playford ED; Ben-Shlomo Y; Clarke CE
Cochrane Database Syst Rev; 2001; (2):CD002814. PubMed ID: 11406045
[TBL] [Abstract][Full Text] [Related]
19. Speech and Language Therapy for Voice Problems in Parkinson's Disease: A Meta-Analysis.
Xu H; Bao Z; Liang D; Li M; Wei M; Ge X; Liu J; Li J
J Neuropsychiatry Clin Neurosci; 2020; 32(4):344-351. PubMed ID: 32374650
[TBL] [Abstract][Full Text] [Related]
20. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
Ramig L; Halpern A; Spielman J; Fox C; Freeman K
Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
